Ingenium Acquires Pivotal Patents for INGENOtyping(TM) Platform
MUNICH, Germany, May 12 /PRNewswire/ -- Ingenium Pharmaceuticals AG has
acquired outright US patents no. 5,994,075 and no. 6,015,670 from Incyte
Corporation , the company announced today. Ingenium previously maintained a
license to these patents, which enabled Ingenium freedom to provide genetic
mouse and rat models, developed using its INGENOtyping(TM) technology, to
partners in the United States. INGENOtyping(TM) is an innovative method for
producing rodent models with subtle gene alterations for use in drug discovery
and development and drug compound testing.
"Acquiring these patents enables us to secure our pole position in developing
and providing genetic rat and mouse models, including knockouts as well hyper-
and hypomorphic models, to our current and future partners in the US,"
commented Michael C. Nehls, M.D., Ph.D., Chief Executive Officer of Ingenium.
"We have seen the value of the INGENOtyping(TM) technology for our internal
research as well as for the drug development efforts at biopharmaceutical
companies across the industry." Ingenium's INGENOtyping(TM) technology is a high-speed method for producing
mouse or rat models that carry unique genetic alterations in any target gene of
interest. These models include knockouts as well as more subtle functional
alterations, such as increased and reduced gene target activity. Ingenium's
INGENOtyping(TM) technology is based on a genetically subtle chemical process
that generates point mutations in genes and Ingenium's expertise in quickly and
reliably producing and analyzing mammalian models of disease.
The basis of Ingenium's business is its knowledge and expertise in generating
the biological information critical to the discovery, validation and
development of therapeutics. Ingenium's drug discovery technologies combine
functional genetics in the rodent model system with proprietary, therapeutic
goal-oriented biological screens and advanced biological pathway analysis. From
the breadth of knowledge generated by the company's Deductive Genomics(R)
technology, Ingenium is currently advancing a portfolio of validated
therapeutic concepts in the areas of inflammation, obesity/diabetes, and
neurobiology. The company's INGENOtyping(TM) platform offers the most rapid
access to innovative rat and mouse models for drug discovery and development
and drug target validation. Ingenium has corporate agreements with multiple
companies, including Bayer AG, Elan Corporation, F. Hoffmann-La Roche Ltd. and
Wyeth, in addition to numerous international academic collaborations.
Ingenium and Deductive Genomics are registered US trademarks.
For more information contact:
Gretchen L.P. Schweitzer
Vice President Corporate Communications
Ph: 49-89-8565-2398
DATASOURCE: Ingenium Pharmaceuticals AG CONTACT: Gretchen L.P. Schweitzer, Vice President Corporate Communications of Ingenium Pharmaceuticals AG, +49-89-8565-2398, Web site: http://www.ingenium-pharmaceuticals.com/
|